Search

Your search keyword '"Chenevix-Trench, G."' showing total 1,518 results

Search Constraints

Start Over You searched for: Author "Chenevix-Trench, G." Remove constraint Author: "Chenevix-Trench, G."
1,518 results on '"Chenevix-Trench, G."'

Search Results

1. Prognostic gene expression signature for high-grade serous ovarian cancer

2. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

3. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

4. Understanding the genetic complexity of puberty timing across the allele frequency spectrum

5. Using polygenic risk modification to improve breast cancer prevention: study protocol for the PRiMo multicentre randomised controlled trial.

6. Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.

7. Prognostic gene expression signature for high-grade serous ovarian cancer

8. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers

9. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

10. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: A combined case-control study

11. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".

12. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

13. Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

14. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

15. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women

16. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

17. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

18. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women

19. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

20. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

21. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

22. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

23. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

24. Rare germline copy number variants (CNVs) and breast cancer risk

25. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

26. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

27. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

28. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

29. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

30. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

31. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

32. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

33. Rare germline copy number variants (CNVs) and breast cancer risk

34. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia.

36. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

37. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study

38. Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25

39. CYP3A7*1C allele:linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

40. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

41. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

42. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

43. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

44. Mendelian randomisation study of smoking exposure in relation to breast cancer risk.

45. Genetic insights into biological mechanisms governing human ovarian ageing.

46. Breast cancer risk genes - Association analysis in more than 113,000 women.

47. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

48. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element.

49. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.

50. Combined Associations of a Polygenic Risk Score and Classical Risk Factors with Breast Cancer Risk.

Catalog

Books, media, physical & digital resources